ProKidney 2024 财年 GAAP 每股收益 $(0.62) 低于预期 $(0.57),第四季度末现金、现金等价物和有价证券为 3.58 亿美元,可支撑运营至 2027 年中旬

财报速递
17 Mar
ProKidney (纳斯达克股票代码:PROK) 报告季度每股亏损 $(0.62),较分析师一致预期的每股亏损 $(0.57) 高 8.77%。相比去年同期每股亏损 $(0.57),这次亏损增加了 8.77%。

以上内容来自Benzinga Earnings专栏,原文如下:

ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 8.77 percent decrease over losses of $(0.57) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10